摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 3-[4-(2-hydroxyethoxy)phenyl]acrylate | 156806-95-0

中文名称
——
中文别名
——
英文名称
methyl 3-[4-(2-hydroxyethoxy)phenyl]acrylate
英文别名
(E)-methyl 3-(4-(2-hydroxyethoxy)phenyl)-acrylate;methyl (E)-3-[4-[2-hydroxyethoxy]-phenyl]-acrylate;methyl (E)-3-[4-(2-hydroxyethoxy)phenyl]prop-2-enoate
methyl 3-[4-(2-hydroxyethoxy)phenyl]acrylate化学式
CAS
156806-95-0
化学式
C12H14O4
mdl
——
分子量
222.241
InChiKey
KHEDMUHUKBPXKZ-QPJJXVBHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    390.7±22.0 °C(Predicted)
  • 密度:
    1.179±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    16
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    55.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    摘要:
    本发明涉及一种包含环糊精和喹唑啉含锌结合基团衍生物的包含复合物的组合物。环糊精最好是β-环糊精或其衍生物。喹唑啉具有增强和意想不到的性质,作为表皮生长因子受体酪氨酸激酶(EGFR-TK)的抑制剂,以及它们在治疗EGFR-TK相关疾病和疾病如癌症中的用途。所述衍生物还可以作为HDAC抑制剂。
    公开号:
    US20090111772A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    摘要:
    本发明涉及一种包含环糊精和喹唑啉含锌结合基团衍生物的包含复合物的组合物。环糊精最好是β-环糊精或其衍生物。喹唑啉具有增强和意想不到的性质,作为表皮生长因子受体酪氨酸激酶(EGFR-TK)的抑制剂,以及它们在治疗EGFR-TK相关疾病和疾病如癌症中的用途。所述衍生物还可以作为HDAC抑制剂。
    公开号:
    US20090111772A1
点击查看最新优质反应信息

文献信息

  • TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    申请人:Cai Xiong
    公开号:US20090076022A1
    公开(公告)日:2009-03-19
    The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors.
    本发明涉及含有锌结合基团的喹唑啉酸盐衍生物,这些衍生物是表皮生长因子受体酪氨酸激酶(EGFR-TK)的抑制剂,以及它们在治疗EGFR-TK相关疾病和疾病如癌症中的用途。这些酒石酸盐还可能作为HDAC抑制剂。
  • Photosensitive compound and its photosensitive polymer
    申请人:Ootsuki Daisuke
    公开号:US08450517B2
    公开(公告)日:2013-05-28
    The invention is to provide a photosensitive compound suitable for a photoalignment method, a photosensitive polymer prepared from the compound, a photoaligning agent by using the compound and a liquid crystal alignment film prepared from the photoaligning agent. A photosensitive compound represented by formula (1): in formula (1), Y1 is a divalent group represented by formula (2-1) or (2-2); A1 is 1,4-phenylene or 1,4-cyclohexylene; Z1 is a single bond, —COO— or —OCO—; R1 and R2 are each independently hydrogen, fluorine or alkyl having 1 to 5 carbons; Q1 is independently a single bond or alkylene having 1 to 12 carbons; and n is 0 or 1. In formulas (2-1) and (2-2), W1 and W2 are each independently hydrogen, alkyl having 1 to 3 carbons or alkoxy having 1 to 3 carbons.
    该发明提供了一种适用于光调向方法的光敏化合物,由该化合物制备的光敏聚合物,利用该化合物制备的光调向剂以及由光调向剂制备的液晶取向膜。一种由式(1)表示的光敏化合物:在式(1)中,Y1是由式(2-1)或(2-2)表示的二价基团;A1是1,4-苯撑基或1,4-环己撑基;Z1是单键,—COO—或—OCO—;R1和R2分别独立地是氢,氟或具有1至5个碳原子的烷基;Q1独立地是单键或具有1至12个碳原子的烷基;n为0或1。在式(2-1)和(2-2)中,W1和W2分别独立地是氢,具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基。
  • Novel Regioselective Ester Hydrolysis by Pig-Liver Esterase
    作者:Amit Basak、Gautam Bhattacharya、Sunanda K. Palit
    DOI:10.1246/bcsj.70.2509
    日期:1997.10
    the hydrolysis of substrates containing both saturated and α,β-unsaturated/cyclopropanecarboxylic esters (methyl and ethyl), was studied. An exclusive hydrolysis of the saturated esters was observed. Kinetic experiments revealed that the presence of deactivated carbonyl in the unsaturated/cyclopropanecarboxylic esters and their weaker bindings are both responsible for the observed specificity. The
    研究了猪肝酯酶,该酶催化含有饱和和 α,β-不饱和/环丙烷羧酸酯(甲基和乙基)的底物水解。观察到饱和酯的唯一水解。动力学实验表明,不饱和/环丙烷羧酸酯中失活羰基的存在及其较弱的结合都是观察到的特异性的原因。已经根据琼斯活性位点模型解释了底物的相对结合能力。区域选择性已被用于合成血栓烷合成酶抑制剂的中间体。
  • CATALYST COMPOSITION INCLUDING ZIRCONIUM COMPOUNDS FOR ESTERFICATION REACTION AND METHOD FOR PREPARING ESTER COMPOUNDS
    申请人:Choi Dai-Seung
    公开号:US20100280265A1
    公开(公告)日:2010-11-04
    The present invention relates to an esterification catalyst composition that includes a zirconium compound and a method for producing an ester compound, which includes the steps of esterifying alcohol and carboxylic acid compounds by using the same, and it may be applied to a mass synthesis process.
    本发明涉及一种酯化催化剂组合物,包括锆化合物,以及一种制备酯化合物的方法,包括使用该组合物酯化醇和羧酸化合物的步骤,可以应用于大规模合成过程。
  • QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    申请人:Qian Changgeng
    公开号:US20080194578A1
    公开(公告)日:2008-08-14
    The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    本发明涉及含有锌结合基团的喹唑啉衍生物,具有增强和意外的抑制表皮生长因子受体酪氨酸激酶(EGFR-TK)的性质,并可用于治疗EGFR-TK相关的疾病和疾病,如癌症。所述衍生物还可以作为HDAC抑制剂。
查看更多